EVALUATION OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS IMMUNOTHERAPY (BELTAVAC®) WITH POLYMERIZED ALLERGENIC EXTRACT OF HOUSE DUST MITE MIXTURE IN PATIENTS WITH ALLERGIC RHINITIS/RHINOCONJUNCTIVITIS

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516893-31-01

Acronym

PRO-RCT-ACAROS-2018

Enrollment

250

Registered

2024-10-18

Start date

2022-01-31

Completion date

Unknown

Last updated

2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinoconjunctivitis due to exposure of house dust mites

Brief summary

Score on the combined scale of nasal symptoms and specific medication (CSMS4) of allergy completed by the patient daily in his/her online patient card in periods of 4 weeks repeatedly during the year of follow-up.

Detailed description

- Nasal symptom scale score (SS4). - Specific medication scale score (MS). - Nasal and ocular symptom scale score (SS6) - Combined nasal, ocular symptom and medication scale score (CSMS6). - Percentage of days without symptoms or medication.

Interventions

DRUGBeltavac Polymerized placebo. It is a saline solution without the allergenic extract

DRUGBELTAVAC with polymerized extract From Dermatophagoides

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Secondary

Measure	Time frame
- Nasal symptom scale score (SS4). - Specific medication scale score (MS). - Nasal and ocular symptom scale score (SS6) - Combined nasal, ocular symptom and medication scale score (CSMS6). - Percentage of days without symptoms or medication.	—

Primary

Measure	Time frame
Score on the combined scale of nasal symptoms and specific medication (CSMS4) of allergy completed by the patient daily in his/her online patient card in periods of 4 weeks repeatedly during the year of follow-up.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026